Acute Stroke on Apixaban: Thrombolysis or Thrombectomy?
A 71-year-old man with atrial fibrillation, hypertension and a prior transient ischemic attack presents 2.5 hours after the sudden onset of right facial droop, dense right arm and leg weakness and expressive aphasia. He takes apixaban 5 mg twice daily; the last dose was 14 hours before symptom onset. NIHSS is 14. BP is 186/98 mmHg, glucose 6.4 mmol/L, weight 82 kg, creatinine 1.3 mg/dL (CrCl about 58 mL/min). Non-contrast CT shows no hemorrhage and an ASPECTS of 8; CT angiography shows a proximal M1 occlusion with good distal collaterals. He has no history of intracranial hemorrhage, recent surgery or bleeding. The stroke team is assembled and the angiography suite is available.
1. Is he eligible for intravenous thrombolysis? Explain your reasoning.
Read the worked answer
No. The last dose of apixaban was 14 hours before symptom onset, which is within the 48-hour window that generally precludes IV thrombolysis in patients taking a direct oral anticoagulant, and there is no readily available coagulation assay confirming normal drug effect. Guidelines do not support giving alteplase or tenecteplase in this situation outside specialist protocols.
Reversal is not routine: idarucizumab is specific to dabigatran and has no role here, and andexanet alfa is not standard treatment before thrombolysis. The correct conclusion is not "do nothing" but "pursue mechanical thrombectomy." The time window, the absence of hemorrhage, the M1 occlusion and the good collaterals make him a strong candidate for endovascular treatment, and anticoagulation is not a contraindication to thrombectomy.
2. What is your endovascular plan, and how would you manage his blood pressure?
Read the worked answer
Proceed urgently to mechanical thrombectomy. He is within 6 hours of onset with a proximal M1 occlusion, NIHSS 14, ASPECTS 8 and good collaterals; he would also qualify for extended-window treatment with favorable perfusion imaging if the clock were later. Do not delay for further coagulation testing.
For blood pressure, lower it to <185/110 mmHg before the procedure and keep it <180/105 mmHg during and after, using labetalol boluses or a nicardipine infusion. His current 186/98 mmHg is just above the pre-procedure threshold. Avoid aggressive lowering, which can worsen penumbral perfusion, and avoid a sudden drop. After successful reperfusion, follow local protocols; some centers target <180/105 mmHg, and the trend matters more than a single reading.
3. What are the antithrombotic and reversal issues after the procedure, including restarting anticoagulation?
Read the worked answer
No reversal agent is needed before thrombectomy. If hemorrhagic transformation occurs, consider andexanet alfa or four-factor prothrombin complex concentrate for apixaban, together with neurosurgical input; there is no widely available specific antidote in every center, so prevention and imaging surveillance matter.
Regarding anticoagulation, do not restart apixaban immediately. The timing depends on infarct size and hemorrhagic transformation: for a small infarct or TIA, restart within 1–2 days; for a moderate infarct, around 4–7 days; for a large infarct or significant hemorrhagic transformation, delay 2–4 weeks. Aspirin is generally not used as a bridge. His apixaban dose of 5 mg twice daily is appropriate for his age, weight and creatinine. Involve neurology and cardiology in a shared decision, and document the reasoning for the chosen restart date.